ADC
-
重磅！一天11款创新药获批！毕井泉被查！中国71项研究口头报告亮相ASCO！脑肠轴重大新突破！恒瑞同日获批3款1类新药！修改教科书的研究成果！中国ADC再次出海。。。
每日发布，持续更新。欢迎广大朋友们关注，一起学习进步！
-
畅聊全球ADC赛道的热点和看点 | 药时代直播间
每年的5月、6月，全球制药领域都显得格外充实忙碌。AACR、ASCO 等顶级盛会先后盛大启幕，参会者数以万计，行业精英齐聚一堂。在这其中，中国企业表现尤为亮眼，特别是在ADC（抗体…
-
【药时代快讯】玛仕度肽临床研究结果顶刊发布；牛俊奇教授畅谈乙肝新药研发；全球医药CVC榜单出炉；央视发布甲状腺眼病纪录片《突破视界》；ADC进军新领域–减重。。。
每日发布，持续更新。欢迎广大朋友们关注，一起学习进步！
-
DLL3 ADC！Two >1B licensing deals by Hengrui/IDEAYA Bio and Innovent Bio/Roche in just 4 days 【Product for Licensing】
If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap. Many thanks!
-
信达生物与罗氏达成新一代DLL3抗体偶联药物的全球独家许可协议
热烈祝贺信达生物和罗氏！
-
A Highly Differentiated EGFR x HER2 Bispecific ADC for Targeted Therapy of Multiple Types of Solid Tumors 【Product for Licensing】
If you are interested in this candidate, please contact DrugTimes BD Team at BD@drugtimes.cn
-
A Highly Differentiated B7-H3 x PSMA Bispecific ADC, Potentially Best-in-Class, for the Treatment of mCRPC 【Product for Licensing】
If you are interested in this candidate, please contact DrugTimes BD Team at BD@drugtimes.cn
-
Merck Halts Two Phase III Clinical Trials
Drug development is not easy, and we pay tribute to the heroes of innovative drug development!
